Physician profile
Judith Mitchell
NPI 1548746019
$7,898.82
in general payments reported to CMS, 2019-2025
48 companies · $1,876 in 2025
The $1,876 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,523 · 2022: $1,463 · 2023: $1,274 · 2024: $1,763 · 2025: $1,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,913.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,389.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,196.16 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $483.76 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $454.66 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $283.18 | 2022-2024 | Spravato, Xarelto |
| Neurocrine Biosciences, INC. | $268.35 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $253.16 | 2022-2024 | |
| Lilly USA, LLC | $211.00 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Corcept Therapeutics | $203.78 | 2021-2024 | Korlym |
| Actelion Pharmaceuticals US, INC. | $196.94 | 2023 | Uptravi, Opsumit |
| Biohaven Pharmaceuticals, INC. | $189.73 | 2021 | |
| Sequel Med Tech, LLC | $182.82 | 2025 | Twiist |
| Glaxosmithkline, LLC. | $162.82 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Inari Medical, INC. | $151.34 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Idorsia Pharmaceuticals US INC | $150.70 | 2023-2024 | Quviviq |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.